近日,海外CRO龙头Medpace公布了2025年第二季度的业绩:公司收入为6.033亿美元,较2024年同期的5.281亿美元增长14.2%,积压订单转化率为21.2%。2025年第二季度税息折旧及摊销前利润(EBITDA)为1.305亿美元,同比2024Q2的1.123亿美元增长16.2%,EBITDA利润率为21.6%。订单方面,2025Q2新增业务合同为6.205亿美元,同比2024Q2的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.